AI assistant
ABBOTT LABORATORIES — Director's Dealing 2022
Feb 24, 2022
29777_dirs_2022-02-23_787af095-900c-4018-bc5e-8942b2ac0b01.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2022-02-18
Reporting Person: Ginascol John F (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-18 | Common shares without par value | A | 17247 | — | Acquired | 130921 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-18 | Option (right to buy) | $117.58 | A | 80380 | Acquired | 2032-02-17 | Common Shares (80380) | Direct |
Footnotes
F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,793 on February 18, 2023, 26,793 on February 18, 2024, and 26,794 on February 18, 2025.